Sign In
Buy RGEN
$121.73
+0.600 (+0.495%)
At Close: Jun 03, 2026
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
02:00pm, Thursday, 20'th Feb 2025
Repligen Corp RGEN released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago but beating the consensus of 41 cents.
Repligen's Q4 Slightly Tops Expectations
11:25am, Thursday, 20'th Feb 2025
Repligen (RGEN 7.92%), a bioprocessing technology company, announced its earnings for the fourth quarter on Feb. 20. Its adjusted earnings per share (EPS) of $0.44 exceeded analysts' consensus estimat
Repligen (RGEN) Beats Q4 Earnings Estimates
09:45am, Thursday, 20'th Feb 2025
Repligen (RGEN) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.33 per share a year ago.
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
07:30am, Tuesday, 11'th Feb 2025
Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET
HRMY vs. RGEN: Which Stock Is the Better Value Option?
12:41pm, Thursday, 30'th Jan 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two stocks present
Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?
04:20am, Wednesday, 29'th Jan 2025
Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Repligen price target lowered to $180 from $240 at H.C. Wainwright
06:06am, Thursday, 23'rd Jan 2025
H.C. Wainwright lowered the firm's price target on Repligen to $180 from $240 and keeps a Buy rating on the shares. The firm says the company could generate solid top- and bottom-line growth in the co
HRMY or RGEN: Which Is the Better Value Stock Right Now?
12:40pm, Tuesday, 14'th Jan 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two co
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
07:30am, Tuesday, 07'th Jan 2025
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate i
Repligen Launches the CTech™ SoloVPE® PLUS System
07:30am, Monday, 06'th Jan 2025
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of i
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
08:11am, Monday, 16'th Dec 2024
BOTHELL, Wash. , Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 12'th Dec 2024
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report
07:30am, Thursday, 12'th Dec 2024
WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of
Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns
07:30am, Monday, 09'th Dec 2024
Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines
Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript
03:07pm, Tuesday, 12'th Nov 2024
Repligen Corporation (NASDAQ:RGEN ) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier
